Editas Medicine (EDIT)

• Market cap: $131M
• 1 day: 6.45%
• 5 days: 6.45%
• 1 month: 42.24%
• 3 months: 20.44%
• 6 months: -45.36%
• Year to date: 25.95%
• 1 year: -68.33%
• 5 years: -92.86%
• 10 years: -90.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Employees: 226

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

7% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 57

2% more call options, than puts

Call options by funds: $396K | Put options by funds: $388K

5.03% less ownership

Funds ownership: 66.84% [Q3] → 61.82% (-5.03%) [Q4]

11% less funds holding

Funds holding: 227 [Q3] → 202 (-25) [Q4]

36% less first-time investments, than exits

New positions opened: 37 | Existing positions closed: 58

65% less capital invested

Capital invested by funds: $188M [Q3] → $64.8M (-$123M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $3 82% upside
• Avg. target: $3 82% upside
• High target: $3 82% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor 31% 1-year accuracy 58 / 187 met price target

82% upside $3

Buy Initiated

28 Apr 2025